Loading...
Please wait, while we are loading the content...
Similar Documents
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Yang, T. S. Wang, Jeng-Yi Tang, Reiping Hsu, Kuan-Cheng Chen, J. Z. S. |
| Copyright Year | 2002 |
| Abstract | BACKGROUND The purpose of this study was to determine the efficacy and toxicity of uracil/ftorafur (UFT) plus oral leucovorin (LV) as first-line chemotherapy for patients with metastatic colorectal cancer and salvage chemotherapy with weekly high-dose 5-fluorouracil (5-FU)/LV 24 h infusion. METHODS Adult patients with no prior chemotherapy for metastatic diseases were enrolled to receive oral UFT 300 mg/m(2)/d plus LV 90 mg/d for 28 days. Treatment was given continuously for 28 days followed by a 7 day rest period from all treatment. For UFT failed patients, weekly 24 h infusion of 5-FU 2600 mg/m(2) plus LV 100 mg/m(2) was used as salvage therapy. RESULTS Fifty-one patients with metastatic colorectal cancer were enrolled in the study. The objective response rate was 29.5% [95% confidence interval (CI), 16.8-45.2%] among the 44 evaluable patients and 25.5% in the intent-to-treat population. The median survival for all 51 patients was 16.6 months. The median time to progression was 5.9 months. Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage. Grade 3 or 4 diarrhea developed in 13.7% of patients. Twenty-six patients were treated with weekly 24 h infusional 5-FU/LV as salvage therapy and only two patients responded. CONCLUSION Our results suggest that this 28 day schedule of UFT/LV regimen may offer a well-tolerated, full oral treatment option with efficacy that appears comparable to that of intravenous 5-FU/LV regimens. Parenteral 5-FU/LV as salvage therapy for UFT refractory patients is not recommended. |
| Starting Page | 1042 |
| Ending Page | 1050 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jjco/32/9/10.1093/jjco/hyf072/3/hyf072.pdf?Expires=1492719006&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=MuuINsEJUrkXJ876payj~DhMgoodJFmg2QsdAcG-QRrLxeJMAerSZDbtsg1nJFOs6CpMxP3wBa~wvth3Wu3seKpNqQIHvu8dSS~3BYI4ku2uEbZvlx54exMmlMMKnbf27NDIM6AU4zG9ngC6yTG11tENAF8HXCSoMCHk-a5r1V7DdS~dn0ieleW9-jS~-KREeO6zhyY1nFGTiH7ci03ziglFgpiHklWQVyh9NRXONcEM9TApRvae3qJmqDxwJOXZRlDqr7UisfH3v27SKJgs3hSMnFHOii~ya3kZu8Kf0FjTLZ7g2zYen9OYOfMXt1IwnQmFjKG2O8HQKt4~nXlszw__ |
| PubMed reference number | 12417601v1 |
| Volume Number | 32 |
| Issue Number | 9 |
| Journal | Japanese journal of clinical oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Colorectal Carcinoma Confidence Intervals Diarrhea Evaluable Disease Fluorouracil Fluorouracil-Leucovorin Regimen (FU-LV Regimen) Leucovorin Non-Small Cell Lung Carcinoma Patients Uracil tegafur-uracil |
| Content Type | Text |
| Resource Type | Article |
